ZimVie (ZIMV) Competitors $9.36 -0.02 (-0.27%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZIMV vs. INMD, BLFS, MDXG, AORT, EYE, ESTA, AXGN, EMBC, IRMD, and BVSShould you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include InMode (INMD), BioLife Solutions (BLFS), MiMedx Group (MDXG), Artivion (AORT), National Vision (EYE), Establishment Labs (ESTA), AxoGen (AXGN), Embecta (EMBC), Iradimed (IRMD), and Bioventus (BVS). These companies are all part of the "medical equipment" industry. ZimVie vs. InMode BioLife Solutions MiMedx Group Artivion National Vision Establishment Labs AxoGen Embecta Iradimed Bioventus ZimVie (NASDAQ:ZIMV) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation. Is ZIMV or INMD more profitable? InMode has a net margin of 45.91% compared to ZimVie's net margin of -77.31%. InMode's return on equity of 18.25% beat ZimVie's return on equity.Company Net Margins Return on Equity Return on Assets ZimVie-77.31% 2.90% 1.17% InMode 45.91%18.25%16.33% Do analysts prefer ZIMV or INMD? ZimVie currently has a consensus target price of $19.50, suggesting a potential upside of 107.89%. InMode has a consensus target price of $21.25, suggesting a potential upside of 36.39%. Given ZimVie's stronger consensus rating and higher probable upside, research analysts plainly believe ZimVie is more favorable than InMode.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZimVie 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00InMode 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more volatility and risk, ZIMV or INMD? ZimVie has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Does the media prefer ZIMV or INMD? In the previous week, ZimVie had 5 more articles in the media than InMode. MarketBeat recorded 7 mentions for ZimVie and 2 mentions for InMode. ZimVie's average media sentiment score of 1.15 beat InMode's score of 0.21 indicating that ZimVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZimVie 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InMode 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in ZIMV or INMD? InMode received 156 more outperform votes than ZimVie when rated by MarketBeat users. Likewise, 72.97% of users gave InMode an outperform vote while only 28.57% of users gave ZimVie an outperform vote. CompanyUnderperformOutperformZimVieOutperform Votes628.57% Underperform Votes1571.43% InModeOutperform Votes16272.97% Underperform Votes6027.03% Do institutionals and insiders hold more shares of ZIMV or INMD? 95.6% of ZimVie shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 3.0% of ZimVie shares are held by insiders. Comparatively, 6.9% of InMode shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, ZIMV or INMD? InMode has lower revenue, but higher earnings than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimVie$449.75M0.58-$393.28M-$0.95-9.87InMode$394.82M2.74$181.27M$2.356.63 SummaryInMode beats ZimVie on 11 of the 19 factors compared between the two stocks. Get ZimVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIMV vs. The Competition Export to ExcelMetricZimVieDental equipment & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.21M$3.56B$5.35B$7.51BDividend YieldN/A2.66%5.44%4.33%P/E Ratio-0.7239.4821.9618.05Price / Sales0.581.28396.51104.31Price / Cash2.776.5738.2034.62Price / Book0.610.606.734.14Net Income-$393.28M-$146.24M$3.21B$247.59M7 Day Performance-0.11%4.42%3.97%3.51%1 Month Performance-18.36%-12.26%-7.03%-5.80%1 Year Performance-40.67%-30.67%15.46%2.83% ZimVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIMVZimVie2.5844 of 5 stars$9.35-0.3%$19.50+108.5%-41.6%$260.37M$449.75M-0.712,700Positive NewsINMDInMode2.0042 of 5 stars$15.08+1.3%$21.25+40.9%-10.3%$1.05B$394.82M6.42480Upcoming EarningsBLFSBioLife Solutions2.1852 of 5 stars$22.08+0.8%$31.17+41.2%+43.1%$1.04B$82.25M-20.83440Positive NewsMDXGMiMedx Group3.1016 of 5 stars$6.77-1.0%$12.00+77.3%+4.1%$997.67M$348.88M12.31870Upcoming EarningsAORTArtivion2.9041 of 5 stars$23.15-0.9%$31.40+35.6%+14.4%$997.64M$388.54M-1,157.501,300News CoveragePositive NewsEYENational Vision1.8708 of 5 stars$11.84+2.6%$14.00+18.2%-37.6%$932.79M$1.82B-59.2014,000Positive NewsESTAEstablishment Labs2.19 of 5 stars$31.32+3.2%$57.40+83.3%-40.1%$903.46M$166.03M-12.14960AXGNAxoGen2.8121 of 5 stars$16.06+1.1%$22.60+40.7%+124.1%$712.17M$187.34M-50.19450Upcoming EarningsPositive NewsEMBCEmbecta4.5577 of 5 stars$11.90-3.3%$20.33+70.9%+3.3%$691.80M$1.11B11.901,900Positive NewsIRMDIradimed4.9006 of 5 stars$53.03+1.4%$72.00+35.8%+25.8%$674.28M$73.24M35.35110Upcoming EarningsNews CoveragePositive NewsGap DownBVSBioventus3.2032 of 5 stars$7.92+5.9%$15.00+89.4%+76.1%$612.94M$573.28M-12.981,200Positive NewsGap Up Related Companies and Tools Related Companies InMode Competitors BioLife Solutions Competitors MiMedx Group Competitors Artivion Competitors National Vision Competitors Establishment Labs Competitors AxoGen Competitors Embecta Competitors Iradimed Competitors Bioventus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIMV) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredA Biotech Power Move? This company is leading the charge in developing advanced antiviral therapies—watch closely!With a revolutionary antiviral drug, this company is in a great position to build shareholder value as this ti...Smallcaps Daily | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZimVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZimVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.